Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Summary as of May 16, 2018

May 16, 2018 - By Glen Chin

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Corporate Logo
Big Money Sentiment increased to 1.22 in 2017 Q4. It has change of 0.01, from 2017Q3’s 1.21. The ratio is positive due to Agios Pharmaceuticals, Inc. positioning: 19 sold and 48 reduced. 27 funds amassed positions and 55 increased positions. Investors holded 44.69 million in 2017Q3 but now own 45.70 million shares or 2.27% more.
Gam Ag stated it has 24,200 shs or 0.04% of all its holdings. C Group Hldgs A S holds 3,200 shs. Bnp Paribas Asset Mgmt Holdg has invested 0.12% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Great West Life Assurance Can holds 5,543 shs or 0% of its capital. Contravisory Mgmt Incorporated owns 5 shs. Wells Fargo And Co Mn holds 71,065 shs or 0% of its capital. Ubs Asset Americas holds 345,284 shs. Barclays Public Ltd holds 0% or 24,030 shs in its capital. Brown Brothers Harriman And has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 53 shs. Balyasny Asset Mngmt Limited Liability holds 0.2% of its capital in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 1.13M shs. New York-based Spark Limited Com has invested 0.04% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Parametric Port Associates Limited Liability owns 22,580 shs. Quantitative Invest Ltd owns 3,600 shs or 0% of their US capital. Blackrock accumulated 2.81M shs or 0.01% of the stock. Sg Americas Secs Ltd Co holds 3,432 shs or 0% of its capital.

Agios Pharmaceuticals, Inc. had 23 insider sales and 1 insider purchase since January 10, 2018. This’s net activity of $18.55 million. Shares for $161,192 were sold by Hoerter Steven L. on Thursday, February 22. Shares for $228,128 were sold by Biller Scott on Monday, February 5. On Thursday, April 12 a trade for 2,000 shs valued at $170,190 was made by Bowden Christopher. Alenson Carman had sold 2,150 shs worth $161,250 on Friday, January 12. $16,688 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shs were bought by Scadden David. 6,800 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shs with value of $557,396 were sold by Foster-Cheek Kaye I.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

In total 4 analysts cover Agios Pharma (NASDAQ:AGIO). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 5 are the (NASDAQ:AGIO)’s analyst reports since November 19, 2017 according to StockzIntelligence Inc. In Sunday, November 19 report SunTrust maintained the stock with “Buy” rating. On Thursday, February 15 JP Morgan maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) with “Overweight” rating. On Wednesday, April 11 the company was maintained by Credit Suisse. On Thursday, February 15 the firm has “Buy” rating by Credit Suisse given. On Wednesday, February 14 RBC Capital Markets maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) with “Buy” rating. Listed here are Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) PTs and latest ratings.

11/04/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $80 New Target: $95 Maintain
15/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $76 New Target: $85 Maintain
15/02/2018 Broker: Credit Suisse Rating: Buy New Target: $80.0 Maintain
14/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $88.0 Maintain
19/11/2017 Broker: SunTrust Rating: Buy New Target: $80.0 Maintain

AGIO reached $86.23 during the last trading session after $0.79 change.Currently Agios Pharmaceuticals, Inc. is uptrending after 41.40% change in last May 16, 2017. AGIO has 53,492 shares volume. The stock outperformed the S&P 500 by 29.85%.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States.The firm is valued at $4.97 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML.Currently it has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

For more Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news brought out recently go to: Streetinsider.com, Streetinsider.com, Seekingalpha.com, Nasdaq.com or Benzinga.com. The titles are as follows: “Agios Pharma (AGIO) PT Raised to $90 at RBC Capital” brought out on May 07, 2018, “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” on May 15, 2018, “Agios Pharmaceuticals’ (AGIO) CEO David Schenkein on Investor Day 2018 Results – Earnings Call Transcript” with a publish date: May 06, 2018, “Agios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results …” and the last “The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap” with publication date: April 29, 2018.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.